Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the launch of a first-to-market generic version of Narcan (naloxone hydrochloride nasal spray), in the US.
Teva said that aloxone hydrochloride nasal spray is a prescription medicine used for the treatment of opioid emergencies such as an overdose or a possible opioid overdose with signs of breathing problems and severe sleepiness, or not being able to respond.
RELATED ARTICLES
With nearly 550 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market, and holds the leading position in first-to-file opportunities, with 100 pending first-to-files in the US Currently, 1 in 12 generic prescriptions dispensed in the US is filled with a Teva generic product.
Teva is currently facing legal proceedings throughout the US in cases alleging its involvement in the manufacture and distribution of highly addictive opioid painkillers.
Published by Globes, Israel business news – en.globes.co.il – on December 23, 2021.
© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
